Screener / SEC EDGAR /CIK 0001668397 /10-K filed Feb 10, 2026, compared with Feb 11, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq Health care · Research Services

Medpace Holdings, Inc. MEDP

We are one of the world’s leading clinical contract research organizations, or CROs, by revenue, solely focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. 10-K, Item 1

Employees
6,200
Headquarters
Cincinnati, OH
CEO
August J. Troendle
Next results
around Feb 8, 2027
Compare with peers Embed

MEDP among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 20.0%, above 75% of 154 peers (their median 10.4%) REVENUE GROWTH 20.0% · above 75% Operating margin: 21.4%, above 81% of 138 peers (their median 9.8%) OPERATING MARGIN 21.4% · above 81% Net margin: 18.2%, above 80% of 153 peers (their median 6.7%) NET MARGIN 18.2% · above 80% FCF margin: 23.5%, above 85% of 144 peers (their median 9.9%) FCF MARGIN 23.5% · above 85% Return on capital: 76.1%, above 100% of 89 peers (their median 9.0%) RETURN ON CAPITAL 76.1% · above 100%
MEDP Peer median Below the median

What changed

4 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 10, 2026 against Feb 11, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

10 checks on the latest 10-K. Checks, not verdicts.

How it works

1fact worth reading about the other 9 checks found nothing to note

  • Receivables growing faster than revenue
    Receivables +35.6% ($296.4M to $402.1M) vs revenue +20.0% ($2.1B to $2.5B), +15.7 pts apart
  • Cash from operations $713.2M vs net income $451.1M (FY ending Dec 31, 2025)
8 more checks with nothing to note
  • Same auditor in both 10-Ks: Deloitte & Touche LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • The same matters as last year: Revenue Recognition - Clinical Research
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

4 paragraphs in Risk Factors that were not in the 10-K filed Feb 11, 2025. Quoted as filed.

All 4 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 11, 2025 10-K, ITEM 1A
    •tariffs imposed by the U.S. government on certain imported goods, equipment, technology, or supplies used in our clinical trials, any retaliatory and/or reciprocal tariffs imposed on U.S. exports by foreign countries, including China, as well as any additional tariffs, duties, or other trade measures or restrictions could increase our…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 11, 2025 10-K, ITEM 1A
    applied and enforced. The materialization of any such risks could have an adverse impact on our financial condition, results of operations, cash flows and reputation.
  3. Item 1A · new paragraph · not in the 10-K filed Feb 11, 2025 10-K, ITEM 1A
    fines or penalties. In addition, negative publicity regarding regulatory compliance of our customers’ clinical trials, programs or products could have an adverse effect on our business and reputation.
  4. Item 1A · new paragraph · not in the 10-K filed Feb 11, 2025 10-K, ITEM 1A
    liable for claims with respect to the actions of third party investigators and the institutions at which clinical trials may be conducted.

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$1.5B$1.9B$2.1B$2.5B
Net income$245.4M$282.8M$404.4M$451.1M
Operating cash flow$388.1M$433.4M$608.8M$713.2M
Free cash flow$351.2M$396.7M$572.3M$681.9M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$2.5B ▲ 20.0% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

8 filings in the last 30 days · SEC EDGAR

All filings
3 more

About the company

Medpace Holdings, Inc., Cincinnati, OH · from the 10-K filed Feb 10, 2026

We are one of the world’s leading clinical contract research organizations, or CROs, by revenue, solely focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Our mission is to accelerate the global development of safe and effective medical therapeutics. We differentiate ourselves from our competitors by our disciplined operating model centered on providing full-service Phase I-IV clinical development services and our therapeutic expertise. We believe this combination results in timely and cost-effective delivery of clinical development services for our customers.

Headquarters
Cincinnati, OH
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Oct 21, 2026
Incorporated in
DE

Employees, at the top of the page: "As of December 31, 2025 we had approximately 6,200 employees located across 46 countries" (10-K). Address and exchange: SEC's company file.

Email alerts

Sources

The 10-K filed Feb 10, 2026 (open at SEC), compared with the 10-K filed Feb 11, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/MEDP/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.